Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III TrialsCesare Gridelli, Francesco Perrone, Paolo Maione et al.|Journal of Clinical Oncology|2018Cited by 70
Effect on quality of life (QOL) of adding cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): A joint analysis of the multicentre, randomized, phase 3 MILES-3 and MILES-4 studiesMaria Carmela Piccirillo, Cesare Gridelli, Alessandro Morabito et al.|Annals of Oncology|2017Cited by 1